Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 37c

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q2 EPS of ($0.69), $0.37 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $268 million versus the consensus estimate of $190.06 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• ExxonMobil Q2 profit falls short of forecasts, shares slide
• AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
• Regal-Beloit (RBC) Tops Q1 EPS by 47c; offers guidance